RE: the truth will come out27 Jul 2021 13:26
Did you read a post a bit furteher up on LinkedIn by aDavid Evans? He wrote to DHSC regarding the Innova test...this was the reply
MHRA RESPONSE - Words fail me - institutionally corrupt
FOI 21/847
Dear Mr Evans,
Thank you for your email of 17 June 2021 in which you requested as follows:
The decision taken to extend the use of the Innova LFT test requires the publication of all the data supporting your decision - please provide me with that data.
We have fully examined the concerns raised by the FDA and?their applicability to the products being supplied by NHS Test and Trace in the UK. Following our normal process to investigate any product concern, the MHRA immediately began reviewing all available information. A full risk assessment was undertaken by the Department of Health and Social Care (DHSC) as a legal manufacturer of the lateral flow devices in the UK and the MHRA were satisfied with the assessment and any action proposed.
Further information can be found on our website: Following a satisfactory review, MHRA extends authorisation of NHS Test and Trace lateral flow devices - GOV.UK (www.gov.uk)
You may be aware that DHSC/Test and Trace have published data on test performance https://lnkd.in/g4BifVZ
Unfortunately, the information you have asked for is exempt from disclosure under Section 44 of the Freedom of Information Act 2000 (FOIA).
Section 44 – Prohibitions on disclosure: the release of information is exempt as its disclosure is prohibited by other legislation. In this case, section 237 of the Enterprise Act 2002 prohibits a public authority from releasing information which came to it in connection with the exercise of its functions, and which relates to the affairs of an individual or business.
The MHRA is satisfied that the information you have requested:
constitutes information which came to us in connection with the exercise of the Agency’s functions. The MHRA has a duty of consumer protection under the Consumer Protection Act 1987 which is listed as a specified function under Schedule 14 of the Enterprise Act 2002, and receives information while exercising consumer protection functions in its role as the regulator of medicines and healthcare products.
relates to the affairs of Innova Medical Group Inc a business which continues to exist.
Sign In
Follow the stocks
